Prognosis of BRCA-associated breast cancer:  a summary of evidence.
The purpose of the study is to review the clinical studies relevant to the prognosis and prognostic associations of BRCA1- and BRCA2-associated breast cancers. Reports of relevant studies obtained from a MEDLINE search and references from these articles were critically reviewed. A number of methodologic limitations have been identified in the early studies. More recent studies have failed to demonstrate, for the most part, a significant overall survival difference between BRCA-associated breast cancers and sporadic breast cancers. The risk of in-breast tumor recurrence also appears to be similar in the first 5 years following a breast cancer diagnosis with apparent increase in the risk after 5 years in one study. Many in-breast tumor recurrences are now considered to be second primary breast cancers. There is a significant increase in the risk of contralateral breast cancers in BRCA mutation carriers with an estimated 10-year risk ranging from 20-40%. The prognosis of BRCA-associated breast cancers appears to be similar to that of sporadic breast cancers based on the current literature. Future data from large prospective cohort studies will be of interest.
Juravinski Cancer Centre, Department of Oncology, McMaster University, Hamilton, ON, Canada. Louise.Bordeleau@jcc.hhsc.ca
L
L
Bordeleau
S
S
Panchal
P
P
Goodwin
D000328:Adult; D051017:Apoptosis Regulatory Proteins; D019313:BRCA1 Protein / Q000096:biosynthesis*; D024682:BRCA2 Protein / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D013997:Time Factors; D016896:Treatment Outcome
D051017:Apoptosis Regulatory Proteins; C118024:BLID protein, human; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human